TriangleNCT02155647 · OUTCOME
Part A: Final Analysis: Overall Survival (OS) Time
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- months
- Interval / dispersion
- Full Range
- Time frame
- Time from first administration of trial treatment until death (Up to 325 weeks)
What was measured
The OS time was defined as the time from first administration of trial treatment until death. The OS time was analyzed using the Kaplan-Meier method.
Analysis population: Intent-to-Treat analysis set included all participants who received at least 1 dose of study treatment.
Groups in this outcome
Part A: Avelumab
Participants with metastatic Merkel cell carcinoma (MCC) after failing first-line chemotherapy received Avelumab at a dose of 10 milligram per kilogram (mg/kg) as 1-hour intravenous infusion once every 2 weeks until therapeutic failure, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product occurs.
| Group | Source count |
|---|---|
| Part A: Avelumab | 88 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part A: Avelumab | 12.6 | Not reported | 0.4 | 71.9 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 0.4
- upper Limit
- 71.9
- value
- 12.6
- denoms
- counts
- group Id
- OG000
- value
- 88
- units
- Participants
- description
- The OS time was defined as the time from first administration of trial treatment until death. The OS time was analyzed using the Kaplan-Meier method.
- dispersion Type
- Full Range
- groups
- description
- Participants with metastatic Merkel cell carcinoma (MCC) after failing first-line chemotherapy received Avelumab at a dose of 10 milligram per kilogram (mg/kg) as 1-hour intravenous infusion once every 2 weeks until therapeutic failure, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product occurs.
- id
- OG000
- title
- Part A: Avelumab
- param Type
- MEDIAN
- population Description
- Intent-to-Treat analysis set included all participants who received at least 1 dose of study treatment.
- reporting Status
- POSTED
- time Frame
- Time from first administration of trial treatment until death (Up to 325 weeks)
- title
- Part A: Final Analysis: Overall Survival (OS) Time
- type
- SECONDARY
- unit Of Measure
- months
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice